Market Cap 1.19B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) N/A
PE Ratio 71.50
Forward PE 85.80
Profit Margin 9.85%
Debt to Equity Ratio 0.00
Volume 1,259,800
Avg Vol 2,425,488
Day's Range N/A - N/A
Shares Out 120.08M
Stochastic %K 73%
Beta 1.06
Analysts Strong Sell
Price Target $24.25

Latest News on DVAX

Dynavax Comments on Glass Lewis Recommendation

Jun 4, 2025, 4:59 PM EDT - 1 day ago

Dynavax Comments on Glass Lewis Recommendation


Deep Track Capital Comments on ISS Recommendation

May 23, 2025, 6:12 PM EDT - 13 days ago

Deep Track Capital Comments on ISS Recommendation


Dynavax Files Preliminary Proxy Statement

Apr 3, 2025, 5:40 PM EDT - 2 months ago

Dynavax Files Preliminary Proxy Statement


Dynavax to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:10 PM EST - 3 months ago

Dynavax to Participate in Upcoming Investor Conferences


Dynavax Advances Board Refreshment Program

Jan 27, 2025, 6:00 AM EST - 4 months ago

Dynavax Advances Board Refreshment Program


Dynavax Announces $200 Million Share Repurchase Program

Nov 7, 2024, 4:01 PM EST - 7 months ago

Dynavax Announces $200 Million Share Repurchase Program


Dynavax Adopts Limited-Duration Stockholder Rights Plan

Oct 29, 2024, 8:30 AM EDT - 7 months ago

Dynavax Adopts Limited-Duration Stockholder Rights Plan


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 9 months ago

3 'Repeatable' Biotech Trades

FOLD GSK NTLA XBI


Dynavax to Present at Upcoming Investor Conferences

May 28, 2024, 4:18 PM EDT - 1 year ago

Dynavax to Present at Upcoming Investor Conferences